Antonio Ianniello

Dr. Antonio Ianniello

Sapienza University of Rome
+1
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2019 in Therapeutic Advances in Neurological Disorders
Verified
Journal Article
Open access
PDF file
Marcello MocciaMarcello Moccia
Marcello Moccia
SRSerena Ruggieri
Serena Ruggieri
AIAntonio Ianniello
Antonio Ianniello
ATAhmed Toosy
Ahmed Toosy
CPCarlo Pozzilli
Carlo Pozzilli
OCOlga Ciccarelli
Olga Ciccarelli
The spinal cord is frequently affected in multiple sclerosis (MS), causing motor, sensory and autonomic dysfunction. A number of pathological abnormalities, including demyelination and neuroaxonal loss, occur in the MS spinal cord and are studied in vivo with magnetic resonance imaging (MRI). The aim of this review is to summarise and discuss recent advances in spinal cord MRI. Advances in conventional spinal cord MRI include improved identification of MS lesions, recommended spinal cord MRI protocols, enhanced recognition of MRI lesion characteristics that allow MS to be distinguished from other myelopathies, evidence for the role of spinal cord lesions in predicting prognosis and monitoring disease course, and novel post-processing methods to obtain lesion probability maps. The rate of spinal cord atrophy is greater than that of brain atrophy (−1.78% versus −0.5% per year), and reflects neuroaxonal loss in an eloquent site of the central nervous system, suggesting that it can become an important outcome measure in clinical trials, especially in progressive MS. Recent developments allow the calculation of spinal cord atrophy from brain volumetric scans and evaluation of its progression over time with registration-based techniques. Fully automated analysis methods, including segmentation of grey matter and intramedullary lesions, will facilitate the use of spinal cord atrophy in trial designs and observational studies. Advances in quantitative imaging techniques to evaluate neuroaxonal integrity, myelin content, metabolic changes, and functional connectivity, have provided new insights into the mechanisms of damage in MS. Future directions of research and the possible impact of 7T scanners on spinal cord imaging will be discussed.

11 October 2020 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
TCTeresa Costabile
Teresa Costabile
ACAntonio Carotenuto
Antonio Carotenuto
LLluigi lavorgna
luigi lavorgna
GBGiovanna Borriello
Giovanna Borriello
LMLucia Moiola
Lucia Moiola
MPMaria Petracca
Maria Petracca

1 June 2020 in Multiple Sclerosis and Related Disorders
Verified
Journal Article
Closed access
GBGiovanna Borriello
Giovanna Borriello
AIAntonio Ianniello
Antonio Ianniello

28 May 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
RNRiccardo Nistri
Riccardo Nistri
AIAntonio Ianniello
Antonio Ianniello
VPValeria Pozzilli
Valeria Pozzilli
Costanza GiannìCostanza Giannì
Costanza Giannì
CPCarlo Pozzilli
Carlo Pozzilli
Brain and spinal cord imaging plays a pivotal role in aiding clinicians with the diagnosis and monitoring of multiple sclerosis. Nevertheless, the significance of magnetic resonance imaging in MS extends beyond its clinical utility. Advanced imaging modalities have facilitated the in vivo detection of various components of MS pathogenesis, and, in recent years, MRI biomarkers have been utilized to assess the response of patients with relapsing–remitting MS to the available treatments. Similarly, MRI indicators of neurodegeneration demonstrate potential as primary and secondary endpoints in clinical trials targeting progressive phenotypes. This review aims to provide an overview of the latest advancements in brain and spinal cord neuroimaging in MS.

16 March 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAntonio Carotenuto
Antonio Carotenuto
Cristiano ScandurraCristiano Scandurra
Cristiano Scandurra
TCTeresa Costabile
Teresa Costabile
LLluigi lavorgna
luigi lavorgna
GBGiovanna Borriello
Giovanna Borriello
RLRoberta Lanzillo
Roberta Lanzillo
Physical disability impacts psychosocial wellbeing in people with multiple sclerosis. However, the role of physical activity in this context is still debated. By taking advantage of a previous survey, conducted online from 22 April to 7 May 2020, we performed a post-hoc analysis with the aim to assess the associations between disability, physical exercise, and mental health in multiple sclerosis. We retrieved the following data: (i) sociodemographic information, (ii) changes in lifestyle (including exercise), (iii) physical disability, as measured with the Patient-Determined Disease Steps scale, and (iv) anxiety feelings and depressive symptoms assessed via the items included in the Quality of Life in Neurological Disorders measurement system. Examination of the interaction plot showed that the effect of disability on depression, but not on anxious symptoms, was significant for all levels of physical exercise (low: b = 1.22, 95% C.I. 0.85, 1.58, p < 0.001; moderate: b = 0.95, 95% C.I. 0.66, 1.24, p < 0.001; and high: b = 0.68, 95% C.I. 0.24, 1.13, p = 0.003). Based on these data, we can conclude that disability significantly impacted depression during the COVID-19 pandemic, with physical activity playing a moderating role. Our results suggest that favoring exercise in multiple sclerosis (MS) would ameliorate psychological wellbeing regardless of the level of physical disability.

26 January 2021 in Journal of Neurology
Verified
Journal Article
Open access
PDF file
MLMatteo Lucchini
Matteo Lucchini
LPLuca Prosperini
Luca Prosperini
MBMaria Chiara Buscarinu
Maria Chiara Buscarinu
DCDiego Centonze
Diego Centonze
ACAntonella Conte
Antonella Conte
MMMassimiliano Mirabella
Massimiliano Mirabella
Background: Dimethyl fumarate (DMF) is an oral drug approved for Relapsing Multiple Sclerosis (RMS) patients. Grade III lymphopenia is reported in 5–10% DMF-treated patients. Data on lymphocyte count (ALC) recovery after DMF withdrawal following prolonged lymphopenia are still scarce. Objectives: To characterize ALC recovery and to identify predictors of slower recovery after DMF interruption. Methods: Multicenter data from RMS patients who started DMF and developed lymphopenia during treatment were collected. In patients with grade II–III lymphopenia, ALCs were evaluated from DMF withdrawal until reaching lymphocyte counts > 800/mm3. Results: Among 1034 patients who started DMF, we found 198 (19.1%) patients with lymphopenia and 65 patients (6.3%) who discontinued DMF due to persistent grade II–III lymphopenia. Complete data were available for 51 patients. All patients recovered to ALC > 800 cells/mm3 with a median time of 3.4 months. Lower ALCs at DMF suspension (HR 0.98; p = 0.005), longer disease duration (HR 1.29; p = 0.014) and prior exposure to MS treatments (HR 0.03; p = 0.025) were found predictive of delayed ALC recovery. Conclusion: ALC recovery after DMF withdrawal is usually rapid, nevertheless it may require longer time in patients with lower ALC count at DMF interruption, longer disease duration and previous exposure to MS treatments, potentially leading to delayed initiation of a new therapy.